Bifogade filer
PDF
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Spotlight |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
As of March 29[th], SelectImmune Pharma AB has signed an agreement with Swedish Orphan Biovitrum (Sobi®) to buy Kineret® (anakinra) and placebo in order to investigate anakinra as a potential treatment of patients with select forms of cystitis and bladder pain syndrome.
Extensive research into the molecular mechanism of cystitis at Lund University has identified interleukin-1 alpha and beta as a major regulator of inflammation and disease in acute cystitis and bladder pain syndrome. The interleukin-1 alpha and beta receptor antagonist (IL1-RA) anakinra has been shown to inhibit inflammation and infection in animal models of cystitis and SelectImmune Pharma is now pursuing clinical trials to further assess the clinical efficacy in these areas.
Kineret (anakinra) is a trademark of Sobi, who markets the drug for various inflammatory conditions, whereas SelectImmune Pharma's patents cover the use of anakinra for the treatment of cystitis and bladder pain syndrome specifically.
The agreement defines that SelectImmune Pharma will conduct clinical trials in these areas with Sobi as the provider of drug and placebo. The parties have the intention to discuss a potential commercialization agreement for the indications protected by SelectImmune Pharma's patent rights.
"We are delighted to have the purchase agreement in place to be able to pursue the studies of the different clinical indications where anakinra has the potential to add value for patients," says Catharina Svanborg, Chairman, SelectImmune Pharma.
"This agreement is of great value to SelectImmune Pharma and we very much look forward to seeing the results of these studies" says Ann Gidner, CEO, SelectImmune Pharma.
For more information, please contact
Catharina Svanborg
Chairman
SelectImmune Pharma AB
Phone +46 709 42 65 49
catharina.svanborg@med.lu.se
Ann Gidner
CEO
SelectImmune Pharma AB
Phone +46 768 17 14 14
ann.gidner@selectImmune.com
This disclosure contains information that SelectImmune is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 29-03-2022 21:38 CET.